341 related articles for article (PubMed ID: 26809131)
1. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
2. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
Jung S; Lee B; Lee KN; Kim Y; Oh EJ
Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
[TBL] [Abstract][Full Text] [Related]
3. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
Gustavsson I; Aarnio R; Myrnäs M; Hedlund-Lindberg J; Taku O; Meiring T; Wikström I; Enroth S; Williamson AL; Olovsson M; Gyllensten U
Virol J; 2019 Aug; 16(1):107. PubMed ID: 31438976
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
7. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
[TBL] [Abstract][Full Text] [Related]
8. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
9. Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population.
Cho HW; Hong JH; Min KJ; Ouh YT; Seong SJ; Moon JH; Cho SH; Lee JK
Cancer Res Treat; 2021 Jul; 53(3):829-836. PubMed ID: 33421987
[TBL] [Abstract][Full Text] [Related]
10. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
12. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
13. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
[TBL] [Abstract][Full Text] [Related]
14. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
[TBL] [Abstract][Full Text] [Related]
16. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
17. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
[TBL] [Abstract][Full Text] [Related]
19. Clinical Evaluation of INNO-LiPA HPV Genotyping
Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]